Key Takeaways for Danaher Stock as of July 2026
- Revenue of $6,265 million beat the $6,170.66 million Street estimate by 1.53%, up 5.54% year over year, and adjusted EPS of $1.94 topped estimates by 4.90%, the clearest sign yet of Danaher stock’s earnings momentum this year.
- Danaher raised full-year adjusted EPS guidance to $8.45-$8.60 from $8.35-$8.55.
- With core revenue excluding respiratory testing up 4.5%, a 150 basis point acceleration from Q1, Life Sciences delivered its strongest quarter in several years at 5.5% core growth.
- But bioprocessing consumables told a different story as CEO Rainer Blair confirmed roughly $100 million in chromatography resin shipments slipped into 2027 on customer site-readiness delays, even as orders grew mid-teens.
Danaher Stock Rides a Beat-and-Raise Quarter Despite a Bioprocessing Pushout
Danaher (DHR) posted a clean beat across nearly every headline metric in the second quarter of 2026, with revenue of $6,265 million topping the $6,170.66 million Street estimate by 1.53% and climbing 5.54% from the $5,936 million reported a year earlier. Adjusted EPS of $1.94 cleared the $1.85 estimate by 4.90%, up 7.78% year over year, while EBITDA of $1,894 million beat by 2.53% and carried a 30.23% margin, 30 basis points wider than the Street modeled.
That strength came from an acceleration investors had been waiting on. Core revenue grew 3% in the quarter, but stripping out declining respiratory testing revenue, core growth ran 4.5%, a 150 basis point pickup from the first quarter. Life Sciences led the way at 5.5% core growth, its best quarter in several years, with Pall’s applied filtration business up roughly 10% on microelectronics demand and Beckman Life Sciences, Leica Microsystems, and SCIEX all contributing.
Bioprocessing told a messier story. Consumables and equipment each grew only low single digits after a handful of large chromatography resin shipments, worth an estimated $50 million to $60 million in the quarter, moved out at customers’ request due to production schedule changes and site readiness issues. CFO Matt Gugino pegged the full-year hit at just over $100 million shifting from Q2 and Q3 into 2027. Management pushed back hard on any read of softening demand. Addressing the swing directly on the Q2 earnings call, CEO Rainer Blair said: “we don’t see any broad-based change in the demand here as you can see by the order data, which refers to both equipment as well as consumables.”
Orders in both categories grew mid-teens during the quarter, and Blair pointed to customer inventory data showing stock levels running below prior-year norms, not above them.
The early close of the Masimo acquisition added its own tailwind. Completed in early June, ahead of schedule, Masimo delivered high single-digit revenue growth and contributed an estimated $0.07 to $0.08 to the raised guide. Danaher lifted full-year adjusted EPS guidance to $8.45-$8.60 from $8.35-$8.55, implying nearly 10% growth at the midpoint, even as management layered in FX and mix offsets as a hedge for the second half. Free cash flow of $1,265 million missed the Street’s $1,358.13 million estimate by 6.86%, though it still grew 15.63% year over year, leaving cash conversion intact even as the quarter’s growth mix shifted.
TIKR Prices Danaher Stock at $275, a 53% Return by 2030
TIKR’s mid-case model values Danaher stock at $275 by December 2030, implying a 53% total return from the current price of $179, or 10% annualized over 4.4 years.
That annualized rate places Danaher stock among steady, mid-single-to-low-double-digit compounders rather than the market’s highest-growth names, a return profile built on core revenue growth compounding through margin expansion rather than multiple re-rating.
The target is reachable on the strength of the Life Sciences acceleration and the raised EPS guide, both of which point to core growth compounding into 2027 as the delayed bioprocessing consumables shipments convert back to revenue. Masimo’s early contribution adds further support, giving Danaher additional earnings power heading into the back half of 2026.
Should You Invest in Danaher Corporation?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up Danaher Corporation stock and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track Danaher Corporation alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Access Professional Tools to Analyze DHR stock on TIKR for Free →
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
